Durbin Letter To USPlabs Targets Latest Supplement Adulterant

USPlabs is under the spotlight again as perennial supplement industry critic Sen. Dick Durbin inquires about the firm’s adverse event records and other regulatory credentials. The latest supplement controversy could bolster Durbin’s efforts to tighten supplement regulations.